US2016310538A1PendingUtilityA1
Transdiscal Administration Of Specific Inhibitors Of Pro-Inflammatory Cytokines
Est. expiryMay 13, 2023(expired)· nominal 20-yr term from priority
A61K 38/363A61K 38/4833A61P 19/00A61K 38/20A61K 38/17A61K 39/3955A61K 38/18A61K 47/34A61K 45/06A61B 17/7061A61K 38/1875A61K 39/395A61K 9/0019C12Y 304/21005A61K 38/1793A61K 9/0085A61K 38/1841G01N 33/6869A61K 9/0012A61K 35/28A61K 35/32G01N 2333/54
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A method of treating a degenerative disease in an orthopedic joint, comprising administering into cartilage of the joint a formulation comprising viable, concentrated, cultured, allogenic, mesenchymal progenitor cells, wherein the cells were obtained from bone marrow aspirate by immunoabsorption with antibodies selected to recognize alkaline phosphatase cell surface antigen.
22 . The method of claim 21 , wherein the antibodies are selected to further recognize STRO-1 cell surface antigen.
23 . The method of claim 22 , wherein the mesenchymal progenitor cells co-express STRO-1 cell surface antigen and alkaline phosphatase cell surface antigen.
24 . The method of claim 23 , wherein the formulation further comprises hyaluronic acid.
25 . The method of claim 24 , wherein the formulation consists essentially of the mesenchymal progenitor cells and hyaluronic acid.Join the waitlist — get patent alerts
Track US2016310538A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.